Apnimed
PublicApnimed is now publicly traded
The data on this page reflects Apnimed's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 31, 2026
Last Round
Debt
Mar 11, 2026
Total Funding Raised
$567.8M
Company Overview
Apnimed is a pharmaceutical company that develops novel oral therapies for the treatment of obstructive sleep apnea and other sleep-related breathing diseases.
Sector
Biotech
Verticals
HealthTech, Life Sciences, LOHAS & Wellness
AI Layer
Non-AI
Keywords
Apnimed Comparables
Compare Apnimed with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incannex Healthcare Inc. | 78% | |
| Mosanna Therapeutics | 75% | |
| Harmony Biosciences Holdings, Inc. | 73% |
For institutional investors. Book with your work email.
Apnimed Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jul 31, 2026 | ||||
| Debt | Mar 11, 2026 | ||||
| Convertible Debt | Sep 17, 2025 | ||||
| IPO | Jun 6, 2025 | ||||
| Series D | Apr 23, 2025 | ||||
Series C Extension | Jan 3, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Apnimed Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Evercore ISI | IPO |
| Ameriprise Financial | Series B |
| HealthCare Royalty Partners | Debt |
| Columbia Threadneedle Investments | Series C, Series C Extension, Series D |
| Morningside Ventures | Series A, Series C, Series B |
| J. & W. Seligman & Company | Series C, Series C Extension, Series B |
| Sectoral | Series C, Series C Extension |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 12, 2026
Apnimed presents five abstracts, including two late-breaking abstracts, at the American College of Chest Physicians' CHEST 2026 Annual Meeting in Arizona from Oct 18-21, 2026.
- has_revenueSep 22, 2026
Apnimed reports $12.1M in quarterly revenue and quarterly EPS of $0.51 on Sep 22nd '26.
- is_developingSep 4, 2026
On Sep 4th '26 in Massachusetts, Apnimed said it is advancing AD109 to improve oxygenation in people with OSA; the candidate has completed two Phase 3 trials, with an NDA PDUFA goal date of Feb '27.
For institutional investors. Book with your work email.
Apnimed Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.